Robert Poulter
President and Chief Executive Officer
Bob joined the company in 2007 in order to move the company from a ‘research and development’ position to commercialization of their products.  A sophisticated individual with high level executive experience in finance, business strategies, mergers and acquisitions, Bob’s experience includes various high level management  positions within the Royal Bank of Canada (Canada’s largest bank), Accenture (a large, global consulting firm), and most recently with IBM’s Business Consulting Division.  Bob’s business experience includes sales, marketing, commercial development, and management in various markets including Canada, USA, Europe, Southeast Asia.

A brief Career Bio  on Robert Poulter

Robert Thayer, PhD
Director, Chairman Emeritus 
As co-founder of the company, Bob’s vision and leadership has taken Genesis Genomics from a small research company into a global leader in the commercialization and clinical application of biomarker discoveries.  Bob has successfully leveraged his previous experience as a professor in Kinesiology and is an Adjunct Professor of Biology at Lakehead University, and a faculty member in the applied biomolecular science program at Lakehead University. His research has focused on protein expression and mtDNA mutations associated with aging, skin cancer, and prostate cancer.

A brief Career Bio  on Robert Thayer

Michael Fawcett
VP Business Development
As the VP of Business Development, Mike is responsible for global relationship management, sales, marketing and driving business value for Genesis Genomics' customers and partners.  Mike has a history of accomplishments in global markets having driven business development for Microsoft's Global Accounts customer segment for seven years in the NY/NJ, Western Europe and most recently Central & Eastern Europe regions.  Prior to Microsoft, Mike held customer centric roles at IBM Canada and Shell Services International.  Mike returns to his hometown of Thunder Bay after 15 years living and working in Winnipeg, Houston, New York and Zurich.  

A brief Career Bio  on Michael Fawcett  

Ryan Parr, PhD
Chief Scientific Officer and VP Research & Development
As co-founder of the company, Ryan has utilized his academic research background in the area of mtDNA to develop Genesis Genomics’ successful commercial research platform and leading edge biomarker discovery capabilities. Ryan began his research career at the University of Utah in the Department of Cellular, Viral, and Molecular Biology. He has participated in a variety of intricate projects such as: nuclear differentiation within eucaryotic cells, mechanisms of viral infections, recovery and sequencing of mtDNA extracted from the skeletal remains of ancient Egyptian populations and, identification of unclaimed victims from the 1912 Titanic disaster using mtDNA. Moreover, as a Senior Research Specialist at the University of Utah Health Sciences Center , Department of Hematology and Oncology, he worked on the problem of cancer resistance to drug therapy.

A brief Career Bio  on Ryan Parr

Prof. Mark Birch-Machin    
Chief Scientific Officer, UK and Chair of Science Advisory Board  
As a co-founder of the company, Mark’s 20 years of experience in Mitochondrial Biochemistry, Molecular Biology, and Dermatology has been a catalyst for the commercialization of Genesis Genomics skin and sun care mtDNA tests and commercial products. He is Professor of Molecular Dermatology at the University of Newcastle, UK and currently holds a Personal Chair in Molecular Dermatology. He received his PhD in Biochemistry in 1987 and has published over 100 times in scientific journals and books. He is considered an international expert in mitochondrial DNA and skin cancer evidenced by his regular appearances as keynote speaker at international conferences and being a press spokesperson for Cancer Research UK, and being featured on international TV News, newspapers, and radio.

A brief Career Bio on Mark Birch-Machin

Jennifer Creed
Chief of Research and Laboratory Operations
Jennifer is an expert researcher with a keen sense of the commercial viability of biomarker discoveries.  Her expertise in research has not only been leveraged to discover new biomarkers, but her laboratory expertise has allowed Genesis Genomics to create and optimize a number of molecular diagnostic tests.  She is a leader in identifying non-invasive approaches to previously invasive molecular tests. Prior to joining the company, Jennifer spent 3 years as a DNA Researcher at Lakehead University’s Paleo-DNA Laboratory.  She holds an Honours Bachelor of Science Degree from Lakehead University where she specialized in biological anthropology.

A brief Career Bio on Jennifer Creed 

Ken Bruley, F.C.A.
Chief Financial Officer
Ken is the former senior partner of Ernst & Young’s Thunder Bay office. He obtained his CA designation in 1967 and was awarded his FCA designation in 1985. Mr. Bruley has dedicated several years to community economic development and has provided expert business advisory, financial expertise, and management consulting services to many former clients. Mr. Bruley was a founding member of the Northwestern Ontario Technology Centre. He has also served as President and member of the Board of Directors for Thunder Bay Ventures, a venture capital and mezzanine finance company focused on economic development.

A brief Career Bio on Ken Bruley